Special Reactive Oxygen Species Generation by a Highly Photostable BODIPY-Based Photosensitizer for Selective Photodynamic Therapy

2013 ◽  
Vol 5 (24) ◽  
pp. 12935-12943 ◽  
Author(s):  
Yen-Chih Lai ◽  
Sheng-Yuan Su ◽  
Cheng-Chung Chang
Biomaterials ◽  
2020 ◽  
Vol 255 ◽  
pp. 120210 ◽  
Author(s):  
Zujian Feng ◽  
Jinxuan Guo ◽  
Xiang Liu ◽  
Huijuan Song ◽  
Chuangnian Zhang ◽  
...  

2010 ◽  
Vol 8 (2) ◽  
pp. 279-291 ◽  
Author(s):  
Venny Santosa ◽  
Leenawaty Limantara

Photodynamic therapy (PDT) is a considerably new kind of photochemotherapeutic treatment in medical field. It combines the use of three components, which are a photosensitizer, light and oxygen. Photosensitizer is a compound activated by light. The application can be oral, topical or intravenous. It usually member of porphyrin group with ampiphilic characteristics. Photosensitizer can be of generation I, II or III, each generation step develops more specificity, selectivity and deeper tissue application. This review will discuss photosensitizer development consecutively, with its benefit and lackness. The light used is usually on red region, while the oxygen is involved in reactive oxygen species generation. Its mechanism action can go through either in type I or type II reaction. This kind of therapy is usually being used in oncology, especially in superficial and in-lining cancers, dermatology and ophthalmology field. This therapy can be safely given to patients with complication and has distinct advantages compare with other treatment such as chemotherapy and surgery. It also considerably has lesser side effects and risks. Broader application is being developed through various experiments and photosensitizer modification.   Keywords: light spectrum, photoactivation, photodynamic therapy, photosensitizer


Author(s):  
Xiaofu Weng ◽  
Zhouzhou Bao ◽  
Xunbin Wei

Photodynamic therapy (PDT) takes advantage of photosensitizers (PSs) to generate reactive oxygen species (ROS) for cell killing when excited by light. It has been widely used in clinic for therapy of multiple cancers. Currently, all the FDA-approved PSs, including porphyrin, are all small organic molecules, suffering from aggregation-caused quenching (ACQ) issues in biological environment and lacking tumor targeting capability. Nanoparticles (NPs) with size between 20[Formula: see text]nm and 200[Formula: see text]nm possess tumor targeting capability due to the enhanced permeability and retention (EPR) effect. It is urgent to develop a new strategy to form clinical-approved-PSs-based NPs with improved ROS generation capability. In this study, we report a strategy to overwhelm the ACQ of porphyrin by doping it with a type of aggregation-induced emission (AIE) luminogen to produce a binary NPs with high biocompatibility, and enhanced fluorescence and ROS generation capability. Such NPs can be readily synthesized by mixing a porphyrin derivative, Ce6 with a typical AIE luminogen, TPE-Br. Here, our experimental results have demonstrated the feasibility and effectiveness of this strategy, endowing it a great potential in clinical applications.


2020 ◽  
Vol 11 (13) ◽  
pp. 3405-3417 ◽  
Author(s):  
Zeyan Zhuang ◽  
Jun Dai ◽  
Maoxing Yu ◽  
Jianqing Li ◽  
Pingchuan Shen ◽  
...  

Phosphindole oxide-based photosensitizers with Type I reactive oxygen species generation ability are developed and used for endoplasmic reticulum stress-mediated photodynamic therapy of tumors.


Nano Research ◽  
2015 ◽  
Vol 8 (6) ◽  
pp. 2004-2014 ◽  
Author(s):  
Zhuo Kang ◽  
Xiaoqin Yan ◽  
Lanqing Zhao ◽  
Qingliang Liao ◽  
Kun Zhao ◽  
...  

ChemPlusChem ◽  
2016 ◽  
Vol 81 (6) ◽  
pp. 515-520 ◽  
Author(s):  
Huaxia Shi ◽  
Wucheng Sun ◽  
Qiang Wang ◽  
Guiying Gu ◽  
Weili Si ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document